

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 August 2023 (31.08.2023)



(10) International Publication Number
WO 2023/164050 A1

(51) International Patent Classification:

A61P 3/00 (2006.01) C07D 405/14 (2006.01)
A61P 9/00 (2006.01) C07D 417/14 (2006.01)
C07D 401/14 (2006.01) A61K 31/498 (2006.01)

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/013700

(22) International Filing Date:

23 February 2023 (23.02.2023)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/313,160 23 February 2022 (23.02.2022) US

(71) Applicant: TERNs PHARMACEUTICALS, INC.

[US/US]; 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US).

(72) Inventors; and

(71) Applicants: LUEHR, Gary W. [US/US]; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). REEVES, Corey [US/US]; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). JONES, Christopher T. [US/US]; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). QUINN, Kevin [US/US]; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US).

(74) Agent: ERLACHER, Heidi A. et al.; Cooley LLP, 1299

Pennsylvania Ave. NW Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: COMPOUNDS AS GLP-1R AGONISTS

(57) Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.



WO 2023/164050 A1